• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors.

作者信息

Touyz Rhian M, Lang Ninian N

机构信息

Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom.

出版信息

JACC CardioOncol. 2019 Sep 24;1(1):37-40. doi: 10.1016/j.jaccao.2019.08.010. eCollection 2019 Sep.

DOI:10.1016/j.jaccao.2019.08.010
PMID:34396160
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8352216/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0e/8352216/30fbeb9c268d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0e/8352216/aba6c75dc2f4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0e/8352216/30fbeb9c268d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0e/8352216/aba6c75dc2f4/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0e/8352216/30fbeb9c268d/gr1.jpg

相似文献

1
Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors.高血压与抗血管生成：VEGF抑制剂的双面性
JACC CardioOncol. 2019 Sep 24;1(1):37-40. doi: 10.1016/j.jaccao.2019.08.010. eCollection 2019 Sep.
2
Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.抗高血压药物对原发性高血压和原发性醛固酮增多症鉴别诊断中醛固酮和肾素浓度的影响。
Clin Endocrinol (Oxf). 2002 Oct;57(4):457-65. doi: 10.1046/j.1365-2265.2002.01613.x.
3
Aldosterone breakthrough from a pharmacological perspective.从药理学角度看醛固酮突破
Hypertens Res. 2022 Jun;45(6):967-975. doi: 10.1038/s41440-022-00913-4. Epub 2022 Apr 14.
4
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.高血压治疗新视角：肾素-血管紧张素-醛固酮系统调节新方法及新兴基于器械的治疗方法。
Eur Heart J. 2011 Nov;32(22):2739-47. doi: 10.1093/eurheartj/ehr253. Epub 2011 Sep 27.
5
Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.患有与慢性肾病相关高血压的猫的血浆肾素活性、血管紧张素I和醛固酮浓度
Am J Vet Res. 1997 May;58(5):535-40.
6
The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.抗高血压药物对原发性醛固酮增多症检测的影响
Front Pharmacol. 2021 May 13;12:684111. doi: 10.3389/fphar.2021.684111. eCollection 2021.
7
Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.他汀类药物、肾素-血管紧张素-醛固酮系统与高血压——他汀类药物另一有益作用的故事
J Renin Angiotensin Aldosterone Syst. 2014 Sep;15(3):250-8. doi: 10.1177/1470320314531058. Epub 2014 Jul 18.
8
Interpreting stimulated plasma renin and aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating drugs.解读刺激后的血浆肾素和醛固酮以选择抵抗性高血压的生理性个体化治疗：刺激药物类别的重要性。
Hypertens Res. 2019 Dec;42(12):1971-1978. doi: 10.1038/s41440-019-0327-2. Epub 2019 Sep 27.
9
Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.在接受血管紧张素转换酶抑制剂/AT1受体阻滞剂治疗的原发性高血压患者中，血浆肾素活性与血浆醛固酮浓度之比与夜间血压及脉压相关。
J Hypertens. 2017 Nov;35(11):2315-2322. doi: 10.1097/HJH.0000000000001438.
10
New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.阻断肾素-血管紧张素-醛固酮系统的新方法：醛固酮受体阻滞剂通过独立于肾素-血管紧张素系统发挥降压和肾脏保护作用。
J Pharmacol Sci. 2010;113(4):310-4. doi: 10.1254/jphs.10r06fm. Epub 2010 Jul 27.

引用本文的文献

1
Unraveling the Complex Molecular Interplay and Vascular Adaptive Changes in Hypertension-Induced Kidney Disease.解析高血压诱导的肾脏疾病中复杂的分子相互作用和血管适应性变化。
Biomedicines. 2024 Aug 1;12(8):1723. doi: 10.3390/biomedicines12081723.
2
Cardiology and oncology: a meeting of giants.心脏病学与肿瘤学：巨头的交汇
Rev Assoc Med Bras (1992). 2024 Jun 7;70(suppl 1):e2024S114. doi: 10.1590/1806-9282.2024S114. eCollection 2024.
3
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.

本文引用的文献

1
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.靶向血管内皮生长因子的酪氨酸激酶抑制剂与血压升高相关。
JACC CardioOncol. 2019 Sep 24;1(1):24-36. doi: 10.1016/j.jaccao.2019.08.012. eCollection 2019 Sep.
2
Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition.肾素-血管紧张素-醛固酮系统在血管内皮生长因子受体抑制过程中调节血压反应。
JACC CardioOncol. 2019 Sep;1(1):14-23. doi: 10.1016/j.jaccao.2019.07.002. Epub 2019 Sep 4.
3
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
一项关于玻璃体内血管内皮生长因子抑制剂对心肾结局影响的系统评价和荟萃分析。
Nephrol Dial Transplant. 2023 Jun 30;38(7):1666-1681. doi: 10.1093/ndt/gfac305.
4
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.两项随机III期试验中接受雷莫西尤单抗治疗的晚期肝癌且甲胎蛋白升高患者的预后和预测因素
Clin Cancer Res. 2022 Jun 1;28(11):2297-2305. doi: 10.1158/1078-0432.CCR-21-4000.
5
Preventive Cardio-Oncology: The Time Has Come.预防性心脏肿瘤学：时机已至。
Front Cardiovasc Med. 2020 Jan 10;6:187. doi: 10.3389/fcvm.2019.00187. eCollection 2019.
血管内皮生长因子抑制剂引起的肾毒性：新证据。
Kidney Int. 2019 Sep;96(3):572-580. doi: 10.1016/j.kint.2019.02.042. Epub 2019 Apr 9.
4
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.真实世界中美国大型索赔数据库中转移性肾细胞癌的治疗模式和不良事件。
BMC Cancer. 2019 Jun 7;19(1):548. doi: 10.1186/s12885-019-5716-z.
5
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.阿昔替尼联合克唑替尼治疗转移性肾细胞癌或其他晚期实体瘤的 Ib 期研究。
Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6.
6
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.三名接受玻璃体内血管内皮生长因子抑制剂注射治疗的患者，随后出现慢性蛋白尿和高血压加重的情况。
Clin Kidney J. 2019 Feb;12(1):92-100. doi: 10.1093/ckj/sfy060. Epub 2018 Jul 27.
7
Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.玻璃体内抗VEGF治疗三种新生血管性年龄相关性黄斑变性亚型的疗效比较：一项系统评价和Meta分析
J Ophthalmol. 2018 Oct 23;2018:1425707. doi: 10.1155/2018/1425707. eCollection 2018.
8
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.癌症治疗的毒性：心脏病专家需要了解的关于血管生成抑制剂的知识。
Heart. 2018 Dec;104(24):1995-2002. doi: 10.1136/heartjnl-2018-313726. Epub 2018 Sep 18.
9
2018 ESC/ESH Guidelines for the management of arterial hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南。
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
10
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017美国心脏病学会/美国心脏协会/美国医师协会/美国心脏病学学会/美国预防医学学院/美国老年病学会/美国药学协会/美国血液学会/美国预防医学学会/美国医学协会/美国初级保健医师学会成人高血压预防、检测、评估和管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13.